Skip to main navigation Skip to search Skip to main content

Hypoglycemia in type 2 diabetes: A critical review

  • Glen H. Murata
  • , William C. Duckworth
  • , Richard M. Hoffman
  • , Christopher S. Wendel
  • , M. Jane Mohler
  • , Jayendra H. Shah

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Hypoglycemia is the most important barrier to tight glycemic control. Although severe hypoglycemia is uncommon, milder events can occur so often that they represent a deterrent to intensifying treatment. High-risk patient behaviors are the most important cause for episodes for which a cause can be identified. Because symptoms are an unreliable way of establishing the diagnosis, SMBG should be considered for the patients at highest risk, particularly as they approach their glycemic targets. SMBG is superior to HbA1c in forecasting the hypoglycemia rate because it provides information about glucose variability--an independent risk factor. Patient education and medication changes are potential ways of reducing the hypoglycemia rate. However, it remains to be proven that patient education is beneficial in this regard.

    Original languageEnglish (US)
    Pages (from-to)551-559
    Number of pages9
    JournalBiomedicine and Pharmacotherapy
    Volume58
    Issue number10
    DOIs
    StatePublished - Dec 2004

    Keywords

    • Diabetes mellitus, type II
    • Hypoglycemia
    • Hypoglycemic agents
    • Insulin
    • Risk factors

    ASJC Scopus subject areas

    • Pharmacology

    Fingerprint

    Dive into the research topics of 'Hypoglycemia in type 2 diabetes: A critical review'. Together they form a unique fingerprint.

    Cite this